About this trial
Title of the Study: Sodium Management Tool in Hemodialysis Patients
Brief Summary:
The goal of this clinical trial is to learn whether the Sodium Management Tool (SMT) can improve patients clnical outcomes.
The main questions this study aims to answer are:
Does the SMT help reduce weight gain between dialysis sessions? Does the SMT improve dialysis tolerance by reducing symptoms like low blood pressure and muscle cramps?
Researchers will compare standard dialysis to dialysis using the SMT to see if clinical outcomes are better in dialysis that use the SMT.
Participants will:
Receive dialysis three times per week with either standard dialysis or SMT-activated dialysis Switch between standard dialysis and SMT-activated dialysis after 4 weeks Have their blood pressure, sodium levels, and symptoms monitored during treatment Report their symptoms and thirst levels in a questionnaire Some participants may continue for an additional 4 weeks with a personalized SMT setting based on their symptoms and weight changes.
This study will help determine whether the SMT can improve sodium balance and make dialysis more comfortable for patients.
Eligibility criteria
Qualifiers
Outpatients on hemodialysis for at least three months,
Dialysis three times a week, age >/= 18,
dialysis with a Fresenius 6008 Machine,
signed informed consent
Disqualifiers
None
Trial design
Treatments tested in this trial
- dialysis assisted with the sodium management tool
Treatment groups
Locations
Sponsors and collaborators
Sharon-Rose Maloney
Lead sponsor
Luzerner Kantonsspital
Sponsor institution